BRIEF COMMUNICATION

Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Yvette Leung MD1, Stefan J Urbanski MD2, Lynn Schindel RN1, Robert P Myers MD1


Rare cases of ischemic colitis associated with interferon-alpha (IFN-α) treatment for chronic hepatitis C (HCV) infection and metastatic cancer have been reported. The present study describes the first case of ischemic colitis attributable to pegylated IFN-α and ribavirin combination therapy in an HCV-infected patient after 34 weeks of treatment. The clinical presentation, endoscopic appearance and histopathology of the colon were consistent with ischemic colitis, and the patient's symptoms rapidly resolved with cessation of therapy.

The association between the therapy and the pathogenesis of ischemic colitis is unclear, but immunoregulatory, vasospastic and procoagulant mechanisms have been proposed. Physicians should be aware of this complication, and should consider it in any HCV-infected patient taking pegylated IFN-α and ribavirin who develops abdominal discomfort and gastrointestinal bleeding.

Key Words: Adverse effects; Colitis; Drug toxicity; Hepatitis C; Interferon; Ischemia; Pegylated interferon-alpha; Ribavirin

Interferons (IFNs) developed by cell culture or recombinant technology have been available for the treatment of hepatitis C virus (HCV) infection since the early 1990s (1). IFN-α acts in vivo to inhibit de novo infection of susceptible cells and to block virion production and release (2,3).

Combination therapy with pegylated (Peg) IFN-α and ribavirin (RBV) leads to a sustained virological response in 42% to 52% of patients with genotype 1 HCV infection (4-6). Common adverse events include influenza-like symptoms, insomnia, irritability and depression. Gastrointestinal symptoms, including nausea, vomiting, anorexia and diarrhea, affect approximately one-third of patients (7). Precipitation or exacerbation of underlying inflammatory bowel disease (8,9) and ischemic colitis (with IFN monotherapy) (10,11) have rarely been reported. In the present report, we describe the first case of ischemic colitis associated with PegIFN-α-2a and RBV combination therapy, with the intention of highlighting this potential complication of antiviral treatment.

CASE PRESENTATION

A 44-year-old Caucasian man presented with a one-day history of acute, left lower quadrant abdominal pain and bloody diarrhea. The patient was on his 34th week of PegIFN-α-2a (Pegasys 180 µg weekly, Hoffmann-La Roche, Canada) and RBV (500 mg twice daily) therapy for chronic HCV (genotype 1b; baseline HCV RNA 1,300,000 U/mL). A pretreatment liver biopsy revealed grade 1 inflammation and stage 1 fibrosis (METAVIR classification) (12), indicative of mild disease. The mode of HCV contamination was unclear, although he admitted to remote intranasal cocaine use. The patient had typical side effects of therapy, including fatigue, flu-like symptoms and insomnia, but did not require dose reductions. He was responding well to treatment as demonstrated by HCV RNA negativity at weeks 12 and 24 (Amplicor HCV Monitor version 2.0, Roche Molecular Diagnostics, Canada; sensitivity 50 IU/mL) and normalization of serum alanine aminotransferase concentration. The patient's past medical history included remote alcohol abuse, depression and a rhinoplasty. He was an active smoker of cigarettes (10 cigarettes daily for 25 years) and cannabis (one to two cigarettes daily for 20 years). The patient denied conventional risk factors for vascular disease including hyperlipidemia, hypertension, diabetes mellitus and a family history of premature coronary artery disease. The patient denied ingestion of illicit drugs (including cocaine), other medications or herbal supplements.

On examination, the patient was afebrile with normal vital signs. Abdominal examination revealed left lower quadrant
tenderness with voluntary guarding and rebound tenderness. A rectal examination revealed bright red blood and external hemorrhoids. Laboratory investigations demonstrated normocytic anemia (hemoglobin level of 97 g/L; normal values 137 g/L to 180 g/L), leukopenia (white blood cell count of 3.7×10^9/L; normal values 4×10^9/L to 11×10^9/L) and thrombocytopenia (platelet count of 103×10^9/L; normal values 150×10^9/L to 400×10^9/L), all attributed to antiviral therapy. Serum electrolyte, creatinine, liver biochemistry, lipase, coagulation profile and venous lactate values were within normal limits. Abdominal radiographs were unremarkable. Flexible sigmoidoscopy demonstrated severe inflammation in the left colon from the sigmoid to the splenic flexure, typical of ischemic colitis (Figure 1). Biopsies revealed superficial loss of the epithelial lining with crypt destruction, congestion and hemorrhage, consistent with ischemic damage (Figure 2) (13). Stool cultures were negative.

A diagnosis of ischemic colitis, possibly related to PegIFN-α-2a and RBV therapy, was made. Antiviral therapy was discontinued, and the patient’s symptoms resolved within three days. The patient did not resume anti-HCV therapy and remains well over six months following initial presentation. His liver biochemistry remains normal and HCV RNA negative, indicative of a sustained virological response despite the truncated course of therapy.

DISCUSSION
Ischemic colitis has been reported in association with a variety of medications (eg, oral contraceptives, vasoconstrictors and 5-hydroxytryptamine agonists/antagonists) and illicit drugs (eg, cocaine and methamphetamine) (14,15). Tada et al (10) and Okanoue et al (11) reported two cases of ischemic colitis in HCV-infected patients receiving high-dose IFN-α monotherapy (10,11). To our knowledge, the patient described is the first case of ischemic colitis attributable to PegIFN-α and RBV combination therapy.

Similar to the patients described by Tada et al (10) and Okanoue et al (11), as well as most patients with ischemic colitis, our patient did not have any conditions that were predisposed to colonic ischemia, such as known atherosclerosis, vasculitides (including HCV-associated cryoglobulinemic vasculitis), thrombophilias or use of vasopressive medications (14,15). We are confident that a causal relationship exists between PegIFN-α and RBV therapy and ischemic colitis in our patient. The temporal relationship, specifically, the rapid resolution following cessation of therapy, is supportive. Although a remote cocaine abuser, he denied recent use. Unfortunately, drug screening was not performed to exclude recidivism. An additional confounding factor in establishing causation in this patient was his daily use of cannabis. Although cannabis has not been reported to cause ischemic colitis, it has been implicated in cases of stroke (16,17), transient ischemic attack (18), paroxysmal atrial fibrillation (19) and sudden cardiac death (20). Moreover, cannabis increases the risk of myocardial infarction 4.8-fold within 1 h following its intake (21). Vasospasm (16,17) and/or an arteritis similar to Buerger’s disease (22) have been proposed as potential mechanisms. Although impossible to prove, the patient’s long-standing use of cannabis without previous ischemic complications and development of recurrent ischemic colitis with ongoing use argue against this being the causative agent in this case. However, cannabis (and cigarette) smoking may have predisposed the patient to ischemic colitis, induced by PegIFN-α/RBV therapy.

Assuming ischemic colitis in our patient was attributable to combination antiviral therapy, determining the offending agent is difficult. While hemolytic anemia attributable to RBV may have contributed to impaired colonic oxygenation (23), RBV has not been reported to be a cause of ischemic colitis. We speculate that PegIFN-α was the major factor, particularly in light of previous reports of an association with other...
Ischemic colitis due to peginterferon and ribavirin

IL-2 therapy, several mechanisms for IFN-induced vascular pathology have been proposed including:

- a direct vasospastic effect (31);
- a procoagulant effect promoting multilocal, arterial thrombotic occlusions (32);
- drug-induced acceleration of lymphocyte attachment to endothelial cells (33); and
- deposition of immune complexes and vasculitis (34).

Clearly, additional study of the molecular mechanisms behind IFN-induced ischemia is warranted.

CONCLUSION

PegIFN-α in combination with RBV is a highly effective treatment for chronic HCV infection. Although rare, ischemic colitis is a potential adverse effect of this therapy. Physicians in all areas of practice should be aware of this complication, and should consider it in any patient taking PegIFN-α and RBV who develops abdominal discomfort and gastrointestinal bleeding.

REFERENCES
